Ascend Capital’s Celldex Therapeutics CLDX Stock Holding History

Ascend Capital’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-58,266	Closed	-$2.48M	–	215
2017 Q4	$2.48M	Sell	58,266 -26,456	-31%	-$1.13M	0.09%	165
2017 Q3	$3.63M	Buy	+84,722	New	+$3.18M	0.14%	117

Other funds holding CLDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ascend Capital's CLDX Position: Q1 2018 in Review

Ascend Capital sold out of Celldex Therapeutics (CLDX) in Q1 2018, closing a stake of 58,266 shares — an estimated $2.48M sold.

Ascend Capital first reported a position in CLDX in Q3 2017 and held it in 2 quarters. The position peaked at $3.63M in Q3 2017. 131 funds tracked by Wall St. Rank hold CLDX as of Q1 2018.

Ascend Capital reported no remaining Celldex Therapeutics position as of Q1 2018 after selling out during the quarter.
Ascend Capital sold 58,266 Celldex Therapeutics shares in Q1 2018, an estimated $2.48M.
Ascend Capital first reported a position in Celldex Therapeutics in Q3 2017 and held it in 2 quarters.
Ascend Capital's Celldex Therapeutics position peaked at $3.63M in Q3 2017.
131 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2018.

Based on Ascend Capital's 13F filing for Q1 2018, filed 14 May 2018.